Monolinuron is a phenylurea herbicide, a derivative of diuron, that is used to control weeds in a variety of crops, including sugar beet, potatoes, and soybeans. It is a selective herbicide, meaning that it kills weeds but not the crop plants. Monolinuron works by inhibiting photosynthesis in weeds, specifically by blocking the electron transport chain in photosystem II. The compound is absorbed through the roots and leaves of weeds. It is generally applied as a pre-emergent herbicide, before weeds have a chance to germinate. Monolinuron is a persistent herbicide, meaning that it can remain active in the soil for an extended period of time. Its persistence can be beneficial for long-term weed control, but it also means that it can be a source of groundwater contamination. The use of monolinuron has been restricted in some countries due to its environmental effects. It is often studied because it is an effective herbicide that can be used to control a variety of weeds, but its environmental persistence and potential for groundwater contamination are also a concern. Monolinuron is synthesized by the reaction of 3-(4-chlorophenyl)-1,1-dimethylurea with 2-chloro-4-nitroaniline. The compound has been shown to be effective in controlling a variety of weeds, including annual grasses, broadleaf weeds, and sedges. It is also being studied for its potential to control aquatic weeds. Monolinuron is a relatively expensive herbicide, but it is effective and can provide long-term weed control.'
monolinuron: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 15629 |
CHEMBL ID | 1320234 |
CHEBI ID | 81965 |
SCHEMBL ID | 65568 |
MeSH ID | M0096771 |
Synonym |
---|
SDCCGMLS-0013702.P002 |
urea, 3-(p-chlorophenyl)-1-methoxy-1-methyl- |
urea, n'-(4-chlorophenyl)-n-methoxy-n-methyl- |
n'-(4-chlorophenyl)-n-methoxy-n-methylurea |
smr000069097 |
MLS000058831 |
monorotox |
caswell no. 207d |
hsdb 5030 |
arezin |
monolinuron [bsi:iso] |
3-(p-chlorophenyl)-1-methoxy-1-methylurea |
aresin |
n-(4-chlorophenyl)-n'-methoxy-n-methylurea |
hoe 02747 |
epa pesticide chemical code 207500 |
premalin |
hoe 2747 |
3-(4-chlorophenyl)-1-methoxy-1-methylurea |
einecs 217-129-5 |
monolinuron |
arezine |
3-(4-chlorphenyl)-1-methoxy-1-methylharnstoff [german] |
brn 2212523 |
AKOS001686898 |
C18794 |
1746-81-2 |
3-(4-chlorphenyl)-1-methoxy-1-methylharnstoff |
6kjj4xad6m , |
unii-6kjj4xad6m |
cas-1746-81-2 |
dtxsid0037576 , |
tox21_301360 |
dtxcid8017576 |
NCGC00255518-01 |
HMS2402C08 |
S10380 |
monolinuron [iso] |
monolinuron [mi] |
monolinuron [hsdb] |
SCHEMBL65568 |
CHEBI:81965 , |
1-methoxy-1-methyl-3-(4-chlorophenyl)urea |
LKJPSUCKSLORMF-UHFFFAOYSA-N |
afesin |
arresin |
CHEMBL1320234 |
1-(4-chlorophenyl)-3-methoxy-3-methylurea |
monolinuron, pestanal(r), analytical standard |
monolinuron 100 microg/ml in acetonitrile |
monolinuron 10 microg/ml in acetonitrile |
J-011027 |
M3269 |
BCP05312 |
mfcd00055264 |
DS-16467 |
Q6901670 |
AMY10726 |
A924734 |
CS-0151364 |
Class | Description |
---|---|
ureas | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
TDP1 protein | Homo sapiens (human) | Potency | 16.3601 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.2434 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 47.6437 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 0.9689 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.2202 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 44.7070 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 24.3365 | 0.0015 | 30.6073 | 15,848.9004 | AID1224849 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 48.5577 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 28.3952 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 34.3762 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 32.9384 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 1.5849 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 0.8913 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 12.5893 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (23.81) | 18.7374 |
1990's | 4 (19.05) | 18.2507 |
2000's | 3 (14.29) | 29.6817 |
2010's | 7 (33.33) | 24.3611 |
2020's | 2 (9.52) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.37) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.76%) | 6.00% |
Case Studies | 3 (14.29%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (80.95%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |